相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。
Article
Oncology
Massimo Rugge et al.
Summary: This study examines the risk of SARS-CoV-2 infection and clinical outcomes in cancer and non-cancer patients. It finds that cancer patients have a lower risk of SARS-CoV-2 infection compared to non-cancer individuals, regardless of the time since cancer diagnosis. However, cancer patients are more likely to be hospitalized and die from COVID-19 compared to non-cancer individuals. The risk of death is particularly high in cancer patients with lung, hematologic, or breast malignancies.
Article
Oncology
Elena Roel et al.
Summary: This study showed that cancer patients have a higher risk of COVID-19 diagnosis, hospitalization, and death compared to non-cancer patients. These associations were stronger for patients recently diagnosed with cancer, under 70 years old, and those with hematological cancers. Therefore, these patients should be prioritized in COVID-19 vaccination campaigns and ongoing non-pharmaceutical interventions.
INTERNATIONAL JOURNAL OF CANCER
(2022)
Article
Oncology
Mariana Chavez-MacGregor et al.
Summary: This study showed that patients with recent cancer treatment and COVID-19 had significantly higher risk of adverse outcomes, while patients with no recent cancer treatment had similar outcomes to those without cancer. The findings have implications for risk stratification and resource allocation for patients, clinicians, and health systems.
Article
Medicine, General & Internal
Csilla Varnai et al.
Summary: This study finds no association between recent systemic anticancer treatments and COVID-19 mortality in patients with active cancer, suggesting that cancer treatments do not inferior outcomes. Differences in outcomes among patients with different cancer types were observed.
Review
Oncology
Gilbert Lazarus et al.
Summary: This meta-analysis aimed to investigate the effects of ICI treatment on COVID-19 prognosis, finding that ICI was not associated with a higher mortality risk, but the quality of evidence for other outcomes was low and further research is needed to confirm the findings.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2022)
Article
Hematology
Petra Langerbeins et al.
Article
Oncology
Qing Wu et al.
Summary: Anti-tumor therapy, especially chemotherapy, increases the risk of severe disease and death for cancer patients with COVID-19. Surgery also increases the risk of death, while targeted therapy increases the incidence of severe COVID-19. Factors such as age, gender, hypertension, COPD, smoking, and lung cancer are potential prognostic factors for death and severe disease in cancer patients with COVID-19.
Article
Health Care Sciences & Services
Ingrid Sperre Saunes et al.
Summary: This paper explores and compares health system responses to the COVID-19 pandemic in Denmark, Finland, Iceland, Norway, and Sweden. The findings suggest differences in implementation and outcomes despite similar policy measures adopted by these countries. Factors such as migrant populations and working conditions may play a role in the variations in outcomes. Additionally, the paper highlights the potential impact of the COVID-19 epidemic on legislation and governance principles in the Nordic countries.
Article
Medicine, General & Internal
Semih Basci et al.
Summary: This study retrospectively investigated data from 926 COVID-19 patients, highlighting that patients with hematologic cancers have a more severe course of the disease, higher rates of ICU admission, MV assistance, longer hospital stays, and a higher case fatality rate compared to patients with solid cancers.
INTERNAL AND EMERGENCY MEDICINE
(2022)
Article
Oncology
David J. Pinato et al.
Summary: During the omicron outbreak, COVID-19 outcomes in cancer patients in Europe improved compared to the prevaccination period and the alpha-delta waves. However, unvaccinated cancer patients remained highly susceptible to SARS-CoV-2. Therefore, our findings support universal vaccination of cancer patients as a protective measure against COVID-19 morbidity and mortality.
Article
Immunology
Heini Salo et al.
Summary: This study aimed to investigate the impact of age and underlying medical conditions on the risk of severe outcomes following SARS-CoV-2 infection and how to prioritize vaccinations against COVID-19 accordingly. The results showed that age and various comorbidities were predictors of severe COVID-19. Vaccine prioritization should take into account both the risk of infection and the risk of severe outcomes if infected.
Article
Oncology
Daniel H. Kwon et al.
Summary: Cancer patients were found to have a decreased risk of SARS-CoV-2 positivity, but certain types of cancer and therapies may increase the risk of hospitalization. However, cancer and therapy types were not associated with severe COVID-19 outcomes.
Article
Oncology
Henri Plais et al.
Summary: This study investigated the mortality among cancer patients requiring organ support in the ICU with SARS-CoV-2 infection, finding that cancer patients had a higher mortality rate, with hematological malignancies carrying a higher risk.
FRONTIERS IN ONCOLOGY
(2022)
Review
Medicine, General & Internal
Emma Khoury et al.
Summary: The study found that patients with cancer and SARS-CoV-2 infection had a higher risk of death compared to those without cancer. Younger age, lung cancer, and hematologic cancer were identified as risk factors associated with poor outcomes from COVID-19.
Article
Infectious Diseases
Tjede Funk et al.
Summary: This study aimed to estimate age-specific associations between underlying conditions and severe COVID-19 outcomes. The findings showed that certain underlying conditions, such as cancer, cardiac disorder, diabetes, immunodeficiency, kidney, liver and lung disease, neurological disorders, and obesity, were associated with an increased risk of hospitalization and death. The risk decreased with increasing age, but for some conditions, the predicted probabilities were higher in younger individuals with the condition compared to older cases without it. The results could inform a more nuanced approach to vaccine prioritization based on age and underlying conditions.
Letter
Oncology
Gunnar Larfors et al.
Article
Oncology
Sultan Abdul-Jawad et al.
Summary: The study found that solid cancer patients exposed to SARS-CoV-2 exhibit immune signatures similar to COVID-19 patients, while hematological cancer patients show more complex immune responses that may affect treatment and recovery. Recovery from SARS-CoV-2 infection leaves distinct immunological legacies in hematological cancer patients.
Article
Oncology
Tom Borge Johannesen et al.
Summary: In this study, researchers aimed to identify factors associated with higher risk of COVID-19 and adverse outcomes among cancer patients. The study found that cancer patients had similar age-adjusted rates of COVID-19 as the general population. Patients who had undergone major surgery within the past 3 months had an increased risk of COVID-19, but no increased risk was found for other oncological treatment modalities. Patients with distant metastases had a significantly increased risk of death due to COVID-19.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
P. Grivas et al.
Summary: This study analyzed clinical factors and laboratory measurements of cancer patients with COVID-19, finding that factors such as age, sex, comorbidities, cancer type, and laboratory results were associated with COVID-19 severity. Patients diagnosed early in the pandemic had worse outcomes, and specific anticancer therapies may increase 30-day all-cause mortality. More research is needed to confirm these findings and caution may be needed in using certain anticancer treatments.
ANNALS OF ONCOLOGY
(2021)
Review
Oncology
Marco Tagliamento et al.
Summary: A systematic review and meta-analysis found that adult patients with solid or hematological malignancies and SARS-CoV-2 infection have a high probability of mortality, with lung cancer patients having a higher case fatality rate (CFR) and breast cancer patients having a lower CFR.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2021)
Article
Oncology
Diego Serraino et al.
Summary: A population-based study conducted in northeastern Italy found that cancer patients have a lower risk of SARS-CoV-2 infection, but they have a higher mortality rate if infected compared to cancer-free individuals. The study highlights the need to continue protecting cancer patients from COVID-19 infection.
Review
Public, Environmental & Occupational Health
Kristina Laugesen et al.
Summary: The Nordic countries provide unique opportunities for joint health registry-based research, but challenges such as cross-border data sharing hinder the full exploitation of their potential. Clear legal pathways and practical frameworks are needed for future collaboration.
CLINICAL EPIDEMIOLOGY
(2021)
Review
Oncology
Amogh Rajeev Nadkarni et al.
Summary: This systematic review and meta-analysis found that critically ill cancer patients with COVID-19 admitted to the ICU had a mortality rate of 60.2%, with cancer patients having higher odds of death compared to noncancer patients. This study highlights the importance of considering admission to the ICU for selected cancer patients with severe COVID-19.
JCO GLOBAL ONCOLOGY
(2021)
Review
Oncology
Robin Park et al.
Summary: This study conducted a systematic review and meta-analysis on the effect of active oncologic treatment on COVID-19 outcomes in cancer patients. The results suggest that active chemotherapy is associated with a higher risk of death, while other treatment modalities did not show significant associations. Further research is needed to understand the complex interactions between active cancer treatment and COVID-19.
Article
Multidisciplinary Sciences
Gareth J. Griffith et al.
NATURE COMMUNICATIONS
(2020)
Editorial Material
Medicine, General & Internal
Reinhard Busse et al.
BMJ-BRITISH MEDICAL JOURNAL
(2013)
